Supriya Lifescience · NSE: SUPRIYA · BSE: 543434
Q4 FY23 results · Jan–Mar 2023
Supriya Lifescience reported revenue from operations of ₹142.27 crore (down 21.5% from Q4 FY22) and net profit of ₹38.23 crore (down 17.3% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 142.27 | 181.27 | −21.5% | 105.14 | +35.3% |
| Other income | 1.96 | 3.85 | −49.0% | 2.56 | −23.4% |
| Total income | 144.23 | 185.12 | −22.1% | 107.70 | +33.9% |
| Profit before tax | 53.29 | 75.48 | −29.4% | 12.64 | +321.4% |
| Net profit for the period | 38.23 | 46.21 | −17.3% | 9.52 | +301.6% |
| EPS, basic (₹) | 4.75 | 5.74 | −17.2% | 1.18 | +302.5% |
| Net margin (%) | 26.9 | 25.5 | 9.1 |
Standalone
- Filed with BSE
- 27 May 2023, 09:37 IST
- Board meeting
- 26 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE